JP2014515036A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014515036A5 JP2014515036A5 JP2014510798A JP2014510798A JP2014515036A5 JP 2014515036 A5 JP2014515036 A5 JP 2014515036A5 JP 2014510798 A JP2014510798 A JP 2014510798A JP 2014510798 A JP2014510798 A JP 2014510798A JP 2014515036 A5 JP2014515036 A5 JP 2014515036A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- maytansinoid immunoconjugate
- maytansinoid
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 39
- 229940127121 immunoconjugate Drugs 0.000 claims 35
- 208000024891 symptom Diseases 0.000 claims 16
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 11
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 11
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 7
- 239000005022 packaging material Substances 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- 230000036210 malignancy Effects 0.000 claims 5
- 230000002411 adverse Effects 0.000 claims 4
- 231100000419 toxicity Toxicity 0.000 claims 4
- 230000001988 toxicity Effects 0.000 claims 4
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 3
- 210000003719 b-lymphocyte Anatomy 0.000 claims 3
- JSHOVKSMJRQOGY-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-(pyridin-2-yldisulfanyl)butanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCSSC1=CC=CC=N1 JSHOVKSMJRQOGY-UHFFFAOYSA-N 0.000 claims 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 2
- 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 claims 2
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 2
- 201000003444 follicular lymphoma Diseases 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 claims 2
- 208000021937 marginal zone lymphoma Diseases 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 229960004641 rituximab Drugs 0.000 claims 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 206010061137 Ocular toxicity Diseases 0.000 claims 1
- 206010044245 Toxic optic neuropathy Diseases 0.000 claims 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims 1
- 230000000735 allogeneic effect Effects 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 239000002619 cytotoxin Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 201000000564 macroglobulinemia Diseases 0.000 claims 1
- 231100000327 ocular toxicity Toxicity 0.000 claims 1
- 238000011476 stem cell transplantation Methods 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 230000003442 weekly effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11290232.5 | 2011-05-17 | ||
| EP11290232A EP2524929A1 (en) | 2011-05-17 | 2011-05-17 | Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms |
| PCT/EP2012/059141 WO2012156455A1 (en) | 2011-05-17 | 2012-05-16 | Use of anti-cd19 maytansinoid immunoconjugate antibody for the treatment of b-cell malignancies symptoms |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016226407A Division JP6181273B2 (ja) | 2011-05-17 | 2016-11-22 | Ｂ細胞悪性腫瘍の症状の治療のための抗ｃｄ１９メイタンシンノイドイムノコンジュゲート抗体の使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014515036A JP2014515036A (ja) | 2014-06-26 |
| JP2014515036A5 true JP2014515036A5 (enExample) | 2014-08-07 |
| JP6050328B2 JP6050328B2 (ja) | 2016-12-21 |
Family
ID=46085972
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014510798A Expired - Fee Related JP6050328B2 (ja) | 2011-05-17 | 2012-05-16 | Ｂ細胞悪性腫瘍の症状の治療のための抗ｃｄ１９メイタンシンノイドイムノコンジュゲート抗体の使用 |
| JP2016226407A Expired - Fee Related JP6181273B2 (ja) | 2011-05-17 | 2016-11-22 | Ｂ細胞悪性腫瘍の症状の治療のための抗ｃｄ１９メイタンシンノイドイムノコンジュゲート抗体の使用 |
| JP2017138852A Pending JP2018021020A (ja) | 2011-05-17 | 2017-07-18 | Ｂ細胞悪性腫瘍の症状の治療のための抗ｃｄ１９メイタンシンノイドイムノコンジュゲート抗体の使用 |
| JP2019087962A Pending JP2019142961A (ja) | 2011-05-17 | 2019-05-08 | Ｂ細胞悪性腫瘍の症状の治療のための抗ｃｄ１９メイタンシンノイドイムノコンジュゲート抗体の使用 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016226407A Expired - Fee Related JP6181273B2 (ja) | 2011-05-17 | 2016-11-22 | Ｂ細胞悪性腫瘍の症状の治療のための抗ｃｄ１９メイタンシンノイドイムノコンジュゲート抗体の使用 |
| JP2017138852A Pending JP2018021020A (ja) | 2011-05-17 | 2017-07-18 | Ｂ細胞悪性腫瘍の症状の治療のための抗ｃｄ１９メイタンシンノイドイムノコンジュゲート抗体の使用 |
| JP2019087962A Pending JP2019142961A (ja) | 2011-05-17 | 2019-05-08 | Ｂ細胞悪性腫瘍の症状の治療のための抗ｃｄ１９メイタンシンノイドイムノコンジュゲート抗体の使用 |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US9555126B2 (enExample) |
| EP (2) | EP2524929A1 (enExample) |
| JP (4) | JP6050328B2 (enExample) |
| KR (1) | KR20140043388A (enExample) |
| CN (2) | CN103547596A (enExample) |
| AR (1) | AR086412A1 (enExample) |
| AU (3) | AU2012258254B2 (enExample) |
| BR (1) | BR112013029330A8 (enExample) |
| CA (1) | CA2835738A1 (enExample) |
| CL (1) | CL2013003272A1 (enExample) |
| CO (1) | CO6821893A2 (enExample) |
| CR (1) | CR20130593A (enExample) |
| DO (1) | DOP2013000260A (enExample) |
| EA (1) | EA028574B1 (enExample) |
| EC (1) | ECSP13013084A (enExample) |
| GT (1) | GT201300276A (enExample) |
| IL (3) | IL229380B (enExample) |
| MA (1) | MA35180B1 (enExample) |
| MX (1) | MX347019B (enExample) |
| MY (1) | MY163736A (enExample) |
| NI (1) | NI201300119A (enExample) |
| PE (1) | PE20141018A1 (enExample) |
| PH (2) | PH12013502305A1 (enExample) |
| SG (2) | SG10201609729VA (enExample) |
| TN (1) | TN2013000468A1 (enExample) |
| TW (3) | TW201834687A (enExample) |
| UA (1) | UA114401C2 (enExample) |
| UY (1) | UY34077A (enExample) |
| WO (1) | WO2012156455A1 (enExample) |
| ZA (1) | ZA201309400B (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2524929A1 (en) * | 2011-05-17 | 2012-11-21 | Sanofi | Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms |
| EP2777714A1 (en) * | 2013-03-15 | 2014-09-17 | NBE-Therapeutics LLC | Method of producing an immunoligand/payload conjugate by means of a sequence-specific transpeptidase enzyme |
| SG11201601037YA (en) | 2013-08-30 | 2016-03-30 | Immunogen Inc | Antibodies and assays for detection of folate receptor 1 |
| CN105837689B (zh) * | 2015-01-13 | 2020-06-19 | 博生吉安科细胞技术有限公司 | 抗cd19单克隆抗体及其制备方法 |
| WO2016180941A1 (en) * | 2015-05-13 | 2016-11-17 | Sanofi | Liquid compositions for anti-cd19 antibody-drug conjugates |
| WO2016189014A1 (en) | 2015-05-26 | 2016-12-01 | Morphosys Ag | Combination of an anti-cd19 antibody and a bruton's tyrosine kinase inhibitor and uses thereof |
| EP3954388A1 (en) | 2015-08-21 | 2022-02-16 | MorphoSys AG | Combinations and uses thereof |
| JP6880006B2 (ja) | 2015-09-17 | 2021-06-02 | イミュノジェン， インコーポレイテッド | 抗ｆｏｌｒ１免疫複合体を含む治療組み合わせ |
| JP2019501139A (ja) | 2015-11-25 | 2019-01-17 | イミュノジェン・インコーポレーテッド | 医薬製剤及びその使用 |
| HRP20210938T1 (hr) | 2016-05-30 | 2021-09-03 | Morphosys Ag | Postupci za prognozu terapijske dobrobiti od anti-cd19 terapije kod pacijenata |
| EP3909985A1 (en) | 2016-06-27 | 2021-11-17 | MorphoSys AG | Anti-cd19 antibody formulations |
| IL320372A (en) | 2016-10-28 | 2025-06-01 | Morphosys Ag | Combination of anti-CD19 antibody with BCL-2 inhibitor and uses thereof |
| WO2018183494A1 (en) * | 2017-03-31 | 2018-10-04 | Immunogen, Inc. | Cd19-targeting antibody-drug conjugates |
| CN110869765A (zh) * | 2017-04-20 | 2020-03-06 | Adc治疗有限公司 | 组合疗法 |
| PL3638373T3 (pl) | 2017-06-14 | 2025-04-14 | Adc Therapeutics Sa | Schematy dawkowania dla podawania ADC anty-CD19 |
| TWI878186B (zh) * | 2017-09-21 | 2025-03-21 | 中國大陸商上海藥明生物技術有限公司 | 新型抗cd19抗體 |
| BR112020005675A2 (pt) | 2017-09-22 | 2020-10-20 | WuXi Biologics Ireland Limited | novos complexos de polipeptideo cd3/cd19 biespecíficos |
| TW201934187A (zh) | 2018-01-12 | 2019-09-01 | 美商免疫遺傳股份有限公司 | 抗體藥物結合、純化、及調配之方法 |
| SG11202110922QA (en) | 2019-04-26 | 2021-10-28 | Immunogen Inc | Camptothecin derivatives |
| SG11202111343TA (en) | 2019-05-03 | 2021-11-29 | Morphosys Ag | Anti-cd19 therapy in patients having a limited number of nk cells |
| AU2020372646A1 (en) | 2019-10-31 | 2022-05-12 | Incyte Corporation | Anti-tumor combination therapy comprising anti-CD19 antibody and gamma delta T-cells |
| CN114599392A (zh) * | 2019-10-31 | 2022-06-07 | 四十七公司 | 基于抗cd47和抗cd20的血癌治疗 |
| PH12022551008A1 (en) | 2019-10-31 | 2023-03-20 | Morphosys Ag | Anti-cd19 therapy in combination with lenalidomide for the treatment of leukemia or lymphoma |
| CN111303286B (zh) * | 2019-12-05 | 2022-05-20 | 常州费洛斯药业科技有限公司 | 一种anti-CD19的全人源抗体或抗体片段及其嵌合抗原受体和应用 |
| WO2021259902A1 (en) | 2020-06-22 | 2021-12-30 | Morphosys Ag | Anti-tumor combination therapy comprising anti-cd19 antibody and polypeptides blocking the sirpα-cd47 innate immune checkpoint |
| TW202229349A (zh) | 2020-10-06 | 2022-08-01 | 美商山可爾股份有限公司 | 用於治療包括全身性紅斑性狼瘡(sle)的自體免疫疾病之生物標記、方法及組合物 |
| CA3204063A1 (en) | 2020-12-04 | 2022-06-09 | Morphosys Ag | Anti-cd19 combination therapy |
| WO2023073645A1 (en) | 2021-10-29 | 2023-05-04 | Takeda Pharmaceutical Company Limited | Therapy comprising anti-cd19 antibody and sumo-activating enzyme inhibitor |
| WO2024038115A1 (en) | 2022-08-17 | 2024-02-22 | Morphosys Ag | Therapy comprising anti-cd19 antibody and ezh2 modulators |
| WO2025087382A1 (zh) * | 2023-10-26 | 2025-05-01 | 上海先博生物科技有限公司 | 靶向cd19的嵌合抗原受体的治疗用途 |
| WO2025157132A1 (en) | 2024-01-23 | 2025-07-31 | Wuxi Biologics (Shanghai) Co., Ltd. | Multispecific antibodies targeting cd3, cd19 and cd20 and uses thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002220265A1 (en) * | 2000-11-03 | 2002-05-15 | University Of Vermont And State Agricultural College | Compositions for inhibiting grb7 |
| EP3524611B1 (en) * | 2003-05-20 | 2020-12-30 | ImmunoGen, Inc. | Improved cytotoxic agents comprising new maytansinoids |
| MX2009002414A (es) * | 2006-09-08 | 2009-05-20 | Medimmune Llc | Anticuerpos anti-cd19 humanizados y su uso en el tratamiento de oncologia, transplante y enfermedad autoinmunitaria. |
| CN102365021B (zh) * | 2009-02-05 | 2015-07-15 | 伊缪诺金公司 | 新型苯并二氮杂*衍生物 |
| JP2012526079A (ja) * | 2009-05-06 | 2012-10-25 | バイオテスト・アクチエンゲゼルシヤフト | Ｃｄ１３８を標的とする免疫複合体の使用 |
| CN102630165A (zh) * | 2009-10-21 | 2012-08-08 | 免疫基因公司 | 一种新的给药方案和治疗方法 |
| EP2524929A1 (en) * | 2011-05-17 | 2012-11-21 | Sanofi | Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms |
| EP2550975A1 (en) * | 2011-07-29 | 2013-01-30 | Sanofi | Combination therapy for the treatment of CD19+ B-cell malignancies symptoms comprising an anti-CD19 maytansinoid immunoconjugate and rituximab |
-
2011
- 2011-05-17 EP EP11290232A patent/EP2524929A1/en not_active Ceased
-
2012
- 2012-05-16 WO PCT/EP2012/059141 patent/WO2012156455A1/en not_active Ceased
- 2012-05-16 CN CN201280023918.7A patent/CN103547596A/zh active Pending
- 2012-05-16 UA UAA201314732A patent/UA114401C2/uk unknown
- 2012-05-16 PH PH1/2013/502305A patent/PH12013502305A1/en unknown
- 2012-05-16 MY MYPI2013004057A patent/MY163736A/en unknown
- 2012-05-16 JP JP2014510798A patent/JP6050328B2/ja not_active Expired - Fee Related
- 2012-05-16 EP EP12721529.1A patent/EP2710034A1/en not_active Withdrawn
- 2012-05-16 PE PE2013002503A patent/PE20141018A1/es not_active Application Discontinuation
- 2012-05-16 SG SG10201609729VA patent/SG10201609729VA/en unknown
- 2012-05-16 SG SG2013083407A patent/SG194894A1/en unknown
- 2012-05-16 EA EA201391714A patent/EA028574B1/ru not_active IP Right Cessation
- 2012-05-16 BR BR112013029330A patent/BR112013029330A8/pt not_active IP Right Cessation
- 2012-05-16 AU AU2012258254A patent/AU2012258254B2/en not_active Ceased
- 2012-05-16 US US14/117,806 patent/US9555126B2/en not_active Expired - Fee Related
- 2012-05-16 KR KR1020137033076A patent/KR20140043388A/ko not_active Abandoned
- 2012-05-16 CA CA2835738A patent/CA2835738A1/en not_active Abandoned
- 2012-05-16 MX MX2013013455A patent/MX347019B/es active IP Right Grant
- 2012-05-16 CN CN201611022631.9A patent/CN107007840A/zh active Pending
- 2012-05-16 AR ARP120101724A patent/AR086412A1/es unknown
- 2012-05-17 UY UY0001034077A patent/UY34077A/es not_active Application Discontinuation
- 2012-05-17 TW TW107102069A patent/TW201834687A/zh unknown
- 2012-05-17 TW TW101117628A patent/TWI601537B/zh not_active IP Right Cessation
- 2012-05-17 TW TW105134320A patent/TW201726167A/zh unknown
-
2013
- 2013-11-11 IL IL229380A patent/IL229380B/en active IP Right Grant
- 2013-11-12 TN TNP2013000468A patent/TN2013000468A1/fr unknown
- 2013-11-12 DO DO2013000260A patent/DOP2013000260A/es unknown
- 2013-11-12 NI NI201300119A patent/NI201300119A/es unknown
- 2013-11-12 GT GT201300276A patent/GT201300276A/es unknown
- 2013-11-13 CR CR20130593A patent/CR20130593A/es unknown
- 2013-11-14 CL CL2013003272A patent/CL2013003272A1/es unknown
- 2013-12-12 MA MA36558A patent/MA35180B1/fr unknown
- 2013-12-12 ZA ZA2013/09400A patent/ZA201309400B/en unknown
- 2013-12-16 EC ECSP13013084 patent/ECSP13013084A/es unknown
- 2013-12-16 CO CO13293559A patent/CO6821893A2/es unknown
-
2016
- 2016-07-21 AU AU2016206317A patent/AU2016206317A1/en not_active Abandoned
- 2016-11-22 JP JP2016226407A patent/JP6181273B2/ja not_active Expired - Fee Related
- 2016-12-16 US US15/381,266 patent/US20170196988A1/en not_active Abandoned
-
2017
- 2017-07-18 JP JP2017138852A patent/JP2018021020A/ja active Pending
- 2017-07-28 PH PH12017501368A patent/PH12017501368A1/en unknown
-
2018
- 2018-02-12 IL IL257475A patent/IL257475A/en unknown
- 2018-03-01 AU AU2018201504A patent/AU2018201504A1/en not_active Abandoned
- 2018-12-16 IL IL263728A patent/IL263728A/en unknown
-
2019
- 2019-05-08 JP JP2019087962A patent/JP2019142961A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014515036A5 (enExample) | ||
| JP6181273B2 (ja) | Ｂ細胞悪性腫瘍の症状の治療のための抗ｃｄ１９メイタンシンノイドイムノコンジュゲート抗体の使用 | |
| TWI596116B (zh) | 包含專一性辨識ｃｄ３８之抗體及硼替佐米（ｂｏｒｔｅｚｏｍｉｂ）之抗腫瘤組合 | |
| TWI549690B (zh) | 包含抗－ｃｄ１９類美登素（ｍａｙｔａｎｓｉｎｏｉｄ）免疫結合物及利妥昔單抗（ｒｉｔｕｘｉｍａｂ）之用於治療ｃｄ１９＋ｂ－細胞惡性症狀之組合療法 | |
| JP2016531915A5 (enExample) | ||
| JP2018500014A5 (enExample) | ||
| JP2014533279A5 (enExample) | ||
| KR20140019298A (ko) | Dlbcl의 치료 수단 및 방법 | |
| JP2016538318A5 (enExample) | ||
| JP2015500822A5 (enExample) | ||
| JP2020536112A (ja) | Ｔ細胞免疫療法のための組合せ及びその使用 | |
| JP2021501776A5 (enExample) | ||
| WO2017066583A1 (en) | A nanomaterial complex comprising graphene oxide associated with a therapeutic agent and methods of use | |
| JP2020510039A5 (enExample) | ||
| JP2015517512A (ja) | Ｃｄ３７抗体の更なる薬剤との併用 | |
| EP2849784A1 (en) | Combination of cd37 antibodies with ice (ifosfamide, carboplatin, etoposide) | |
| JP2016525560A5 (enExample) | ||
| JP2024028865A (ja) | 抗ｃｄ１９抗体とベネトクラクスとの組み合わせ治療のための治療パラダイム | |
| Anastasia et al. | Novel drugs in follicular lymphoma | |
| US20230014026A1 (en) | Anti-Tumor Combination Therapy comprising Anti-CD19 Antibody and Polypeptides Blocking the SIRPalpha-CD47 Innate Immune Checkpoint | |
| JP2015516980A (ja) | Ｃｄ３７抗体とベンダムスチンとの併用 | |
| Doubek et al. | Treatment of chronic lymphocytic leukemia with monoclonal antibodies, where are we heading? | |
| Stathis et al. | New agents for the treatment of lymphoma | |
| US20160106837A1 (en) | Combination of cd37 antibodies with chlorambucil | |
| TW202408575A (zh) | 奧布替尼與ｔａｆａｓｉｔａｍａｂ聯合用藥治療 |